4D Molecular Therapeutics reported revenue of $3.78M and net income of -$72.94M for the quarter ended Jun 2026. This income statement covers 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||
| Revenue | 1.37M | 0.09M | 1.22M | 0.16M | 0.50M | 1.25M | 0.30M | 0.24M | 20.20M | -0.02M | 0.03M | 0.01M | 0.00M | 0.00M | 0.01M | 0.01M | 0.09M | 85.09M | 3.05M | 3.78M | |||||||
| Operating items | |||||||||||||||||||||||||||
| Research & DevelopmentR&D | 15.84M | 17.53M | 19.38M | 20.42M | 18.94M | 21.50M | 22.41M | 23.58M | 25.07M | 26.03M | 27.87M | 31.86M | 38.48M | 43.09M | 40.70M | 47.95M | 49.44M | 57.61M | 64.98M | 68.28M | |||||||
| Selling, General & AdministrativeSG&A | 8.19M | 7.33M | 8.23M | 8.17M | 8.05M | 8.47M | 7.99M | 8.79M | 9.11M | 10.61M | 10.29M | 10.60M | 12.65M | 13.03M | 12.94M | 11.52M | 11.84M | 12.77M | 11.69M | 12.52M | |||||||
| Operating ExpensesOpex | 24.03M | 24.86M | 27.61M | 28.59M | 27.00M | 29.97M | 30.40M | 32.38M | 34.18M | 36.63M | 38.16M | 42.46M | 51.13M | 56.12M | 53.63M | 59.47M | 61.27M | 70.38M | 76.67M | 80.81M | |||||||
| Operating IncomeOp. Inc | -22.66M | -24.76M | -26.39M | -28.43M | -26.50M | -28.72M | -30.11M | -32.14M | -13.97M | -36.65M | -38.14M | -42.46M | -51.13M | -56.12M | -53.62M | -59.46M | -61.19M | 14.71M | -73.62M | -77.03M | |||||||
| EBIT | -22.66M | -24.76M | -26.39M | -28.43M | -26.50M | -28.72M | -30.11M | -32.14M | -13.97M | -36.65M | -38.14M | -42.46M | -51.13M | -56.12M | -53.62M | -59.46M | -61.19M | 14.71M | -73.62M | -77.03M | |||||||
| Non-operating items | |||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.43M | -0.31M | -1.00M | -0.41M | 0.80M | 1.34M | 0.93M | 0.61M | 3.88M | 4.38M | -0.12M | -0.18M | 7.29M | 6.47M | 0.10M | 4.86M | 4.33M | 4.70M | -0.91M | 4.25M | |||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.01M | -0.01M | -0.05M | 0.01M | 0.00M | -0.02M | 0.01M | -0.16M | -0.01M | -0.01M | -0.04M | -0.00M | -0.02M | 0.07M | -0.06M | -0.02M | -0.02M | -0.00M | -0.17M | ||||||||
| Non Operating IncomeNon Op. Inc. | 0.42M | -0.32M | 0.05M | 0.34M | 0.80M | 1.34M | 1.42M | 2.52M | 3.72M | 4.37M | 5.74M | 7.50M | 7.29M | 6.45M | 5.65M | 4.80M | 4.31M | 4.68M | 4.86M | 4.09M | |||||||
| Net income details | |||||||||||||||||||||||||||
| EBT | -22.23M | -25.08M | -27.39M | -28.83M | -25.70M | -27.38M | -29.18M | -31.52M | -10.10M | -32.27M | -38.26M | -42.64M | -43.84M | -49.65M | -53.52M | -54.60M | -56.85M | 19.42M | -74.53M | -72.77M | |||||||
| Profit After TaxPAT | -22.24M | -25.08M | -26.34M | -28.09M | -25.69M | -27.38M | -28.68M | -29.62M | -10.26M | -32.28M | -32.40M | -34.95M | -43.84M | -49.67M | -47.97M | -54.66M | -56.88M | 19.40M | -68.76M | -72.94M | |||||||
| Income from Continuing OperationsIncome (Continuing) | -22.23M | -25.08M | -27.39M | -28.83M | -25.70M | -27.38M | -29.18M | -31.52M | -10.10M | -32.27M | -38.26M | -42.64M | -43.84M | -49.65M | -53.52M | -54.60M | -56.85M | 19.42M | -74.53M | -72.77M | |||||||
| Consolidated Net IncomeConsol Net Inc. | -22.23M | -25.08M | -27.39M | -28.83M | -25.70M | -27.38M | -29.18M | -31.52M | -10.10M | -32.27M | -38.26M | -42.64M | -43.84M | -49.65M | -53.52M | -54.60M | -56.85M | 19.42M | -74.53M | -72.77M | |||||||
| Income towards Parent CompanyParent Net Inc | -22.23M | -25.08M | -27.39M | -28.83M | -25.70M | -27.38M | -29.18M | -31.52M | -10.10M | -32.27M | -38.26M | -42.64M | -43.84M | -49.65M | -53.52M | -54.60M | -56.85M | 19.42M | -74.53M | -72.77M | |||||||
| Net Income towards Common StockholdersNet Income | -22.24M | -25.08M | -26.34M | -28.09M | -25.69M | -27.38M | -28.68M | -29.62M | -10.26M | -32.28M | -32.40M | -34.95M | -43.84M | -49.67M | -47.97M | -54.66M | -56.88M | 19.40M | -68.76M | -72.94M | |||||||
| Additional items | |||||||||||||||||||||||||||
| EPS (Basic) | -0.82 | -0.90 | -0.82 | -0.87 | -0.79 | -0.85 | -0.88 | -0.77 | -0.24 | -0.83 | -0.66 | -0.63 | -0.79 | -0.92 | -0.86 | -0.98 | -1.01 | 0.33 | -1.01 | -1.04 | |||||||
| EPS (Diluted) | -0.82 | -0.90 | -0.82 | -0.87 | -0.79 | -0.85 | -0.88 | -0.77 | -0.24 | -0.83 | -0.66 | -0.63 | -0.79 | -0.92 | -0.86 | -0.98 | -1.01 | 0.33 | -1.01 | -1.04 | |||||||
| Shares Outstanding | 27.02M | 27.73M | 32.23M | 32.32M | 32.39M | 32.35M | 32.72M | 38.34M | 42.26M | 39.13M | 49.27M | 55.28M | 55.55M | 53.94M | 55.74M | 55.93M | 56.13M | 57.93M | 68.06M | 70.27M | |||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 27.02M | 27.73M | 32.23M | 32.32M | 32.39M | 32.35M | 32.72M | 38.34M | 42.26M | 39.13M | 49.27M | 55.28M | 55.55M | 53.94M | 55.74M | 55.93M | 56.13M | 57.93M | 68.06M | 70.27M | |||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 27.17M | 32.22M | 32.26M | 32.38M | 32.39M | 32.63M | 33.24M | 42.02M | 42.75M | 43.08M | 51.16M | 51.91M | 52.00M | 45.79M | 46.32M | 46.70M | 46.77M | 57.61M | 68.06M | 70.27M | |||||||
| EBITDA | -22.66M | -24.76M | -26.39M | -28.43M | -26.50M | -28.72M | -30.11M | -32.14M | -13.97M | -36.65M | -38.14M | -42.46M | -51.13M | -56.12M | -53.62M | -59.46M | -61.19M | 14.71M | -73.62M | -77.03M |